Increased Atherosclerosis in Mice Deficient in Perilipin1.
Dominique Langlois, Fabien Forcheron, Jacques-Yuan Li, Peggy del Carmine, Samia Neggazi, Michel Beylot

To cite this version:
Dominique Langlois, Fabien Forcheron, Jacques-Yuan Li, Peggy del Carmine, Samia Neggazi, et al.. Increased Atherosclerosis in Mice Deficient in Perilipin1.. Lipids in Health and Disease, BioMed Central, 2011, 10 (1), pp.169. 10.1186/1476-511X-10-169. inserm-00629632

HAL Id: inserm-00629632
https://www.hal.inserm.fr/inserm-00629632
Submitted on 6 Oct 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Increased Atherosclerosis in Mice Deficient in Perilipin1

Dominique Langlois1, Fabien Forcheron1, Jacques-Yuan Li1, Peggy del Carmine1,2, Samia Neggazi1 and Michel Beylot1,2*

Abstract

Background: Perilipin1, a lipid droplet associated protein has an important role in the regulation of lipolysis and lipid storage in adipocytes. Perilipin1 is also expressed in foam cells of atheroma plaques and could therefore play a role in the accumulation of lipids in arterial wall and in the development of atherosclerosis. The aim of the study was to investigate this possible role of perilipin1 in atherogenesis.

Methods: Mice deficient in perilipin1 (Plin1-/-) were crossed with Ldlr-/- mice. Ldlr-/- and Plin1-/- Ldlr-/- mice received an atherogenic diet during 10 or 20 weeks. Blood pressure and plasma lipids concentrations were measured. Aortas were collected at the end of the atherogenic diet periods for quantification of atheroma lesions (en face method), histological and immunohistological studies.

Results: Ldlr-/- and Plin1-/- Ldlr-/- mice had comparable blood pressure and plasma lipids levels. Plin1-/- Ldlr-/- mice had a lower body weight and decreased adiposity. The atherosclerotic lesion area in Plin1-/-Ldlr-/- mice was moderately increased after 10 weeks of atherogenic diet (ns) and significantly higher after 20 weeks (p < 0.01). Histology of atheroma plaques was comparable with no sign of increased inflammation in Plin1-/- Ldlr-/- mice.

Conclusion: Perilipin1 ablation in mice results in increased atherosclerosis independently of modifications of risk factors such as raised blood pressure or plasma lipids levels. These data strongly support an atheroprotective role for perilipin1.

Keywords: perilipin1, atherosclerosis, lipids

Introduction

A hallmark of atherosclerosis is the accumulation of free (FC) and esterified (EC) cholesterol in macrophages and smooth muscular cells transforming them in foam cells [1]. Such accumulation depends on the balance between the uptake of cholesterol-rich lipoprotein through scavenger receptors [2] and the efflux of free cholesterol controlled by the transporters ABCA1 and ABCG1 [3] and to a lesser extent by SR-B1 (or CLA-1) [4,5]. This accumulation depends also on the intra-cellular metabolism of cholesterol, particularly the balance between its free and esterified forms. CE taken up by cells is hydrolyzed in lysosomes to FC that is then directed to various cell membranes by the protein NPC1 [6]. Excessive accumulation of FC has toxic effects on cells [7] and FC must be either removed through efflux to extra-cellular acceptors or esterified. CE is then stored in lipid droplets and can be removed from cells only after hydrolysis to FC by a cholesterol ester hydrolase, whose nature is still debated [8-10].

Storage of lipid droplets in cells accumulating triacylglycerols (adipocytes, hepatocytes) or EC (steroidogenic cells) is also dependent in part of specific proteins surrounding these droplets and belonging to the PERILIPIN family (previously named PAT family) [11], particularly perilipin1 (previously perilipin) and perilipin2 (previously adipophilin or ADRP). Perilipin2 is present in all cells storing lipids [12]. Its expression is increased during incubation of macrophages with oxidized LDL [13,14]. It is expressed in foam cells of atherosclerotic plaques [14]. Its overexpression in THP-1 macrophages enhances lipid accumulation [15] whereas its invalidation protects against atherosclerosis [16]. Therefore perilipin2 is clearly
involved in atheroma. Perilipin1 has at least three different forms, perilipin1 A, B and C, resulting from alternative splicing of a common premessenger RNA [17]. Perilipin1 A and B are present in adipocytes, the A form being largely predominant. Perilipin1 C is found in steroidogenic cells. In adipocytes, perilipin1 opposes in the basal state hydrolysis of triacylglycerols. β-adrenergic agents phosphorylate perilipin1 on specific serine sites and phosphorylated perilipin1 allow phosphorylated HSL to hydrolyze TG. Perilipins1 are thus implicated in the regulation of basal and stimulated lipolysis. Perilipin1 A is expressed in macrophages [18-21] and vascular smooth muscular cells [18], in arterial wall [18] and is overexpressed in atheroma plaques [18,22], particularly unstable plaques [22]. Perilipin1 could therefore be implicated in the development of atherosclerosis by controlling the hydrolysis of stored EC. The overexpression of perilipin1 in atheroma plaque could favour the accumulation of cholesterol and promote the development of atheroma. However, perilipin1 could also shift the balance between FC and EC toward EC and help to prevent excessive accumulation of FC. Since excess FC is toxic for cells and plays a role in the evolution of plaques toward instability [7,23], perilipin1 could have on the contrary a protective role. In a first step to clarify this issue and to determine the role, if any, of perilipin1 in atheroma, we investigated the effect of perilipin1 invalidation on the development of atheroma in an experimental model, the Ldlr-/- mouse.

Methods

Plin1-/- mice were a gift from I Tabas (Columbia University, NY, USA). These mice are from the strain generated and described by Martinez-Botas et al [24] and are on a C57BL/6 background. Ldlr-/- mice (C57BL/6 background) were from the Jackson Laboratory (Bar Harbor, ME, USA). Plin1-/- and Ldlr-/- mice were crossed to obtain Plin+/+Ldlr +/- mice, which were intercrossed to obtain Ldlr-/- and Plin1-/-Ldlr-/- mice. All mice were housed in an animal facility with controlled temperature (21-23°C) and lighting (light on 07:00, light off 19:00) and had free access to food and water. Male mice were used for the experiments. These mice received, starting at 8 weeks of age, an atherogenic diet (38.4% fat, 0.15% cholesterol, U8958 version 52 from SAFE, Augy, France) and saline, carefully cleaned of perivascular adipose tissue and flash frozen in liquid nitrogen before storage at -80°C until analysis. Total RNAs were purified using TRIZOL protocol (Invitrogen, Cergy-Pontoise, France) with the addition of a DNase treatment. Concentrations, integrity and purity were verified. For measurements of individual mRNA levels (IL-6, IL-1β, TNFa, MCP-1, SR-A, ABCA1, ABCG1), total RNA was reverse transcribed using Superscript II (Invitrogen) and random hexamers. Real time PCR was performed in a MyIQ thermal cycler (Biorad, Marnes La Coquette, France) using iQ SYBR green Supermix (Biorad). Samples were run along with dilutions of known amounts of target sequence for quantification of initial cDNA copies. Results were calculated as the target over 18S RNA concentration ratio (ng/µg). Primer sequences are shown in table 1.

Results are shown as individual values or as means ± sem. Comparisons between groups were performed by Student t test for non paired values or by Mann-Whitney U test for paired values. Comparisons between groups were performed by Student t test for non paired values or by Mann-Whitney U test for paired values. Comparisons between groups were performed by Student t test for non paired values or by Mann-Whitney U test for paired values.
Whitney test using GraphPad Prism (version 5.03). P < 0.05 was considered as indicating a significant difference.

**Results**

Plasma cholesterol levels were high in both Plin1<sup>−/−</sup> Ldlr<sup>−/−</sup> and Ldlr<sup>−/−</sup> mice but did not differ between the two groups of mice (table 2). Plasma triacylglycerols levels were comparable. Systolic blood pressure (111.5 ± 3.1 vs 116.5 ± 6.6 mmHg in Ldlr<sup>−/−</sup> mice) and heart rate (547 ± 25 vs 515 ± 23 b/min) were also comparable. Plin1<sup>−/−</sup> Ldlr<sup>−/−</sup> had a slightly lower body weight (10 weeks: 25.2 ± 0.4 vs 27.8 ± 0.7g p < 0.01; 20 weeks: 27.6 ± 0.5 vs 30.0 ± 0.9g p < 0.05) and as expected [24] an evident decrease at examination of fat pads volume. Despite these comparable blood pressure and plasma lipids levels and decreased fat mass, Plin1<sup>−/−</sup> Ldlr<sup>−/−</sup> mice had after 10 weeks of atherogenic diet a trend for increase in atherosclerosis (figure 1) as quantified by the *en face* method. This increase was significant (+55%, p < 0.01) at 20 weeks. Figure 2 shows a representative sample of the extent of lesion in aortas from Plin1<sup>−/−</sup> Ldlr<sup>−/−</sup> and Ldlr<sup>−/−</sup> mice. Histological examination of plaques performed on aortas from mice fed since 20 weeks the atherogenic diet showed no differences in structure (elastic lamellae, fibrosis, cellularity) between Plin1<sup>−/−</sup> Ldlr<sup>−/−</sup> and Ldlr<sup>−/−</sup> mice (figure 3). The abundance of lymphocytes and macrophages estimated by immunocyto-ology (figure 4) was comparable and there was no evidence of increased inflammation in plaques of Plin1<sup>−/−</sup> Ldlr<sup>−/−</sup> mice. In addition we found no increase in the mRNA levels of MCP-1, IL-6 or IL1-β (data not shown) and only a non significant trend for higher values of TNFα mRNA (1.72 ± 0.37 10<sup>−4</sup> vs 1.13 ± 0.26 10<sup>−5</sup> ng/μg 18S RNA p = 0.10) in aortas from Plin1<sup>−/−</sup> Ldlr<sup>−/−</sup> mice. The expression of SR-A, implicated in the uptake of modified lipoproteins, and of ABCA1 and ABCG1, controlling the efflux of cholesterol, were increased in aortas of Plin1<sup>−/−</sup> Ldlr<sup>−/−</sup> mice (respectively 3.59 ± 1.06 10<sup>−1</sup> vs 4.81 ± 1.09 10<sup>−2</sup>, 5.85 ± 1.53 10<sup>−3</sup> vs 2.94 ± 1.03 10<sup>−4</sup> and 7.17 ± 2.95 10<sup>−4</sup> vs 1.44 ± 0.45 10<sup>−5</sup> ng/μg 18S RNA, p < 0.05 for all).

**Discussion**

The present results support an atheroprotective role of perilipin1 since the extent of atheroma lesions was increased in Ldlr<sup>−/−</sup> mice with perilipin1 ablation. The overall histological appearance of the plaques was unchanged and we observed no increase in macrophages or lymphocytes infiltration, nor any significant increase in the mRNA concentrations of pro-inflammatory cytokines and chemokines. Therefore inflammation does not

|                   | Total cholesterol g/l | Triacylglycerols g/l |
|-------------------|-----------------------|---------------------|
|                   | Ldlr<sup>−/−</sup>    | Ldlr<sup>−/−</sup> | Plin1<sup>−/−</sup> | Ldlr<sup>−/−</sup> | Ldlr<sup>−/−</sup> | Plin1<sup>−/−</sup> |
| 10 weeks          | 9.99 ± 0.71           | 10.07 ± 0.96        | 1.32 ± 0.20         | 1.34 ± 0.55       |
| 20 weeks          | 8.56 ± 1.39           | 9.79 ± 0.32         | 0.75 ± 0.34         | 1.02 ± 0.38       |

Results are shown as mean and sem.
appear increased and the enhanced atheroma seems to result mainly form an increase in lipid deposits. Such an increase is demonstrated by the examination of aortas by the en face method since Red Sudan IV stains lipid deposits. An increased expression of SR-A could contribute to this increase in lipid deposits. The increase in ABCA1 and ABCG1 expression would on the contrary favour cholesterol efflux and could be an adaptative response to the increased accumulation of intra-cellular cholesterol. Perilipin1 can be found in macrophages and vascular smooth muscular cells and is present within atheroma plaques in foam cells originating from both cell types [18-22]. We used mice with a global invalidation of perilipin1 and cannot delineate the respective roles of macrophages and smooth muscular cells perilipin1 in the evolution of atheroma. This will need investigating mice with tissue specific invalidation. We cannot exclude an indirect effect on atheroma of perilipin1 ablation outside of the vasculature, i.e. in adipose tissue. However, blood pressure and plasma lipid levels were unaffected while body weight and fat mass (as appreciated by fat pads volume) were reduced by perilipin1 ablation. Therefore we can exclude a role for three major risk factors for atheroma (hypertension, higher plasma lipid levels, obesity) in the enhanced atherosclerosis we observed. Physical activity was also unchanged (data not shown) in agreement with previous reports [26]. Perilipin1 invalidation induces however some peripheral insulin-resistance, despite the reduced adiposity [27]. We cannot exclude a role for such insulin-resistance.

**Conclusion**

In conclusion we found a protective role of perilipin1 against atherosclerosis. Evaluation of the respective roles of perilipin1 in macrophages and in smooth muscular cells and elucidation of the precise mechanisms implicated will require further studies.
Acknowledgements
This study was supported by grants from the ALFEDIAM and from the Fondation de France.

Author details
1IR22-EA4173, Faculté Rockefeller, University C Bernard Lyon1, 8 av Rockefeller, Lyon, 69008, France. 2AniRA-ANIPHY, Faculté Rockefeller, University C Bernard Lyon1, 8 av Rockefeller, Lyon, 69008, France.

Authors’ contributions
DL had in charge the mice strains and performed with JYL the quantification of atheroma and histological studies. FF and PDC had in charge mice strains and collected data, particularly plasma lipids and blood pressure. SN had in charge mRNA determinations. MB designed the study and wrote the manuscript. All authors participated in the analysis of data and the preparation of the manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 30 June 2011 Accepted: 24 September 2011 Published: 24 September 2011

References
1. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 1995; 57:791-804.
2. De Winter M, Hoffer M. Scavenging new insights into atherogenesis. J Clin Invest 2000; 105:1039-1041.

Figure 4 Immunocytoology of atheroma plaques of Ldlr-/- (panels A, C, E) and Plin-/- Ldlr-/- (panels B, D, F) mice. Specific staining was performed with anti-Mac3 (macrophages, panels C and D), anti-CD3 (lymphocytes panel E and F) and anti-αSMA (smooth muscular cells, panel A and B) antibodies. Representative sections of atheroma plaques are shown. Scale: 100 μm.
3. Cavaliere CL, Rohrer L, von Eckardstein A: Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1. Biochim Biophys Acta 2006, 1765:655-666.

4. Chiniatti G, Obaguidi F, Grigolo S, Mallat Z, Antonucci M, Pouilain P, Chapman J, Fruchart J, Tedgui A, Nabi-Fruchart J, et al: CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000, 101(2411-2417).

5. Chen W, Silver D, Smith J, Tall A: Scavenger receptor-Bi inhibits ATP-binding cassette transporter 1 mediated cholesteryl ester efflux in macrophages. J Biol Chem 2000, 275:30794-30800.

6. Liscum L, Klusek J: Nieman-Pick disease type C. Curr Opin Lipidol 1998, 9:131-135.

7. Tabas I: Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J Clin Invest 2002, 110:905-911.

8. Contreras J, Launon C: Essential differences in cholesterol ester metabolism between human monocyte derived and J774 macrophages: evidence against the presence of HSL in human macrophage. Atheroscler Thromb Vasc Biol 1993, 14:443-452.

9. Ghosh S: Cholesterol ester hydrolase in human monocyte/macrophage: cloning, sequencing, and expression of full length cDNA. Physiol genomics 2000, 2:1-8.

10. Khoo J, Reue K, Steinberg D, Schotz M: Expression of HSL mRNA in macrophages. J Lipid Res 1993, 34:1069-1074.

11. Kimmel AR, Brasseme DL, McAndrews-Hill M, Sataly C, C: Adoption of PERILIPIN as a unifying nomenclature for the mammalian PAT-family of intracellular lipid storage droplet proteins. J Lipid Res 2010, 51:468-471.

12. Heid H, Moll R, Schenkel I, Richter H, Keenan T: Adipophilin is a specific marker of lipid accumulation in diverse cell types ans diseases. Cell Tissue res 1998, 294:309-321.

13. Buechler C, Ritter M, Duong C, Orso E, Kapinsky M, Schmitz G: Expression of adipophilin mRNA in human macrophages stimulated with oxidized low-density lipoprotein and in atherosclerotic lesions. Atherosclerosis 2001, 153:145-150.

14. Wang X, Reape T, Li X, Rayner K, Webb C, Burnand H, Lysko P: Induced expression of adipophilin mRNA in human macrophages stimulated with oxidized low-density lipoprotein and in atherosclerotic lesions. FEBS Lett 1999, 462:145-150.

15. Largauderie G, Furman C, Jaye M, Lasselin C, Copin C, Fruchart J, Castro G, Rouis M: Adipophilin enhances lipid accumulation and prevents lipid efflux from THP-1 macrophages: potential role in atherogenesis. Arterioscler Thromb Vasc Biol 2004, 24:504-510.

16. Paul A, Chang BH-J, Li L, Yechoor VK, Chan L: Deficiency of Adipose Differentiation-Related Protein Impairs Foam Cell Formation and Protects Against Atherosclerosis. Circulation Research 2008, 102(12):1492-1501.

17. Lu XG-G, Coppeland NG, Gilbert DJ, Jenkins NA, Londos C, Kimmel AR: The murine perilipin gene: the lipid droplet-associated perilipins derive from tissue-specific, mRNA splice variants and define a gene family of ancient origin. Mamm Genome 2001, 12:741-749.

18. Forchonon F, Legedz L, Chinetti G, Feugier P, Letexier D, Brica G, Beylot M: Genes of cholesterol metabolism in human atheroma: overexpression of perilipin and genes promoting cholesterol storage and repression of ABCA1 expression. Atherosclerosis 2005, 24:504-510.

19. Højsgaard OBI, Schnoor M, Lorkowski S, Robenek H: Expression of perilipin isoforms in cell types involved in atherogenesis. Atherosclerosis 2007, 190:14-15.

20. Largauderie GB, Furman C, Jaye M, Fruchart JC, Rouis M: Perilipin, a potential substitute for adipophilin in triglyceride storage in human macrophages. Atherosclerosis 2006, 189:142-148.

21. Persson JOE, Nilsson J, Lindholm MW: Perilipin and adipophilin expression in lipid loaded macrophages. Biochem Biophys Res Commun 2007, 363:1020-1026.

22. Faber B, Krietmair C, Nissen R, Aarts P, Boon W, AS G, Ktitsa P, Tordoir J, Daemen M: Identification of genes potentially involved in rupture of human atherosclerotic plaques. Circ Res 2001, 89:547-554.

23. Yao P, Tabas I: Free cholesterol loading of macrophages induces apoptosis involving fas pathway. J Biol Chem 2000, 275:23807-23813.

24. Martinez-Botas J, Anderson J, Teissier D, Lapillonne A, Chang B, Quast M, Gorenstein D, Chen K, L C: Absence of perilipin results in leanness and reverses obesity in Lepr/db/db mice. Nat Genet 2000, 26:474-479.